Background: Statins are among the most widely prescribed medications worldwide
Introduction
Glycosylation is a complex, highly specific and regulated co-and posttranslational process that covalently links glycans (complex oligosaccharides) to proteins and lipids [1, 2] . Structural variations in the attached glycans strongly affect structure and function of proteins. Nearly all human plasma proteins, with exception of albumin, are modified by glycans [3, 4] . Structural differences in terminal glycan antennae is common and recent studies demonstrated significant variation in glycome composition both within and between individuals [5] [6] [7] . Glycosylation is not only age-and gender-specific but is also affected by many environmental factors such as smoking, diet and medication [6, [8] [9] [10] . Furthermore, glycosylation patterns have been characterized in relation to cardiovascular disease risk [11, 12] . In particular decrease in immunoglobulin G (IgG) galactosylation has been associated with adverse cardiometabolic risk factors, including: cholesterol, triglycerides, Creactive protein (CRP), HbA1c, insulin, glucose, body mass index (BMI) and kidney disease [13] [14] [15] .
Statins, also known as HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, are among the most widely prescribed medications in the world. They are first-line drugs in the treatment of hypercholesterolemia and for cardiovascular prevention due to their efficacy in lowering LDL-cholesterol and
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6 reducing cardiovascular morbidity and mortality [16, 17] . However, more recent experimental and clinical investigations have revealed that statins are also potent anti-inflammatory agents that exert beneficial effects beyond LDL-cholesterol reduction [18, 19] .
Both glycans and statins are connected with inflammation processes.
Glycosylation is changing in many inflammatory diseases [20] and minor changes in glycan composition can have a profound influence on IgG effector functions by modulating binding to Fc receptors, and can convert IgG from a pro-inflammatory into an anti-inflammatory agent [21] [22] [23] . Moreover, it has been shown that use of statins is associated with expression of some glycosyltransferases in leukocytes and the expression of those glycosyltransferases was also changed in coronary syndrome patients [12] . Furthermore, many individuals involved in clinical and population studies are on statin therapy. If use of statins influences glycome composition, it could bias the results of glycomic studies. Therfore, it would be biologically and clinically relevant to know how statins relate to IgG glycomes. In this study we analyzed the association of statins with N-glycosylation of IgG in two large population cohorts (TwinsUK and KORA). Afterwards we investigated the same association for only one statin (rosuvastatin) in a subset of samples from the randomized double-blind placebo-controlled JUPITER study.
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Material and methods
Study Subjects
This study was based on plasma samples obtained from three cohorts -the TwinsUK, the KORA and the JUPITER study. The demographic characteristics of the study populations are presented in Table 1 . Written informed consent was obtained from all participants.
TwinsUK registry is a national register of adult twins. Twins were recruited as volunteers by successive media campaigns without selecting for particular diseases or traits [24] . Statin drug status was gathered for 2247 individuals (328 cases and 1919 controls) with glycan data available. Statins included atorvastatin, simvastatin, fluvastatin, pravastatin and rosuvastatin.
German population study KORA F4 [25] ("Kooperative Gesundheitsforschung in der Region Augsburg"), included 1665 samples with statin drug status (257 cases and 1408 controls) and available glycan data. Statins included atorvastatin, simvastatin, fluvastatin, pravastatin and lovastatin.
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Justification for the Use of Statins in Primary Prevention: An Intervention Trial
Evaluating Rosuvastatin trial (JUPITER; www.ClinicalTrials.gov; NCT00239681) [19] was a double-blind, placebo-controlled trial that evaluated rosuvastatin 20 mg daily versus placebo in the primary prevention of first major CVD events in healthy men ≥50 years and women ≥60 years with low-density lipoprotein cholesterol <130 mg/dL, but who were at increased risk of cardiovascular events on the basis of elevated high-sensitivity C-reactive protein (≥2 mg/L).
IgG isolation
Immunoglobulin G was isolated from plasma by affinity chromatography using 96-well protein G monolithic plates (BIA Separations, Ljubljana, Slovenia) as described previously [7] . Briefly, 100 µL of plasma was diluted 10× with PBS, filtered was expressed as % of total integrated area. The system was calibrated using an external standard of hydrolyzed and 2-AB labeled glucose oligomers from which the retention times for the individual glycans were converted to glucose units [26] .
Glycans were analyzed on the basis of their elution positions and measured in glucose units then compared to reference values in the "Glyco-Base" database (available at: http://glycobase.nibrt.ie) for structure assignment [27] . For IgG
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glycans, in addition to 24 directly measured glycan traits, 52 derived traits were calculated. These derived traits average particular glycosylation features (galactosylation, fucosylation, bisecting GlcNAc, and sialylation) (Supplementary Table 1 ). 
IgG tryptic digestion and purification
25
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LC-ESI-MS/MS analysis of IgG tryptic glycopeptides
Tryptic digests were analyzed on nanoACUITY UPLC system (Waters, USA)
coupled to micrOTOF-Q mass spectrometer (BrukerDaltonics, Bremen, Germany). 9
µL of eluates containing IgG tryptic glycopeptides was loaded into Acclaim PepMap100 C8 (5mm×300 μm i. Table 1 ).
Statistical Analysis
Statistical analysis was carried out using Stata version 12 and R (version 3.1.2) and visualized using the ggplot2 package.
Glycans were globally normalized and log transformed to account for the right-skewness of their distributions. To remove experimental biases, all measurements were adjusted for batch and run-day effects using ComBat (Rpackage sva). Derived glycan traits were calculated using normalized and batch-
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15 corrected glycan measurements (exponential of batch corrected measurements). All variables were centered and scaled to have mean 0 and standard deviation 1.
Outliers (more than 6SD from the mean) were excluded from the analysis.
Association analyses between statin use and glycan traits were performed using linear mixed regressions adjusting for age, sex, BMI in KORA cohort, and in the TwinsUK cohort, with additional adjustment for family relatedness as random effect.
We used Bonferroni correction to account for multiple testing in the TwinsUK cohort (P=0.05/77≈6x10 -4 ).
For the TwinsUK cohort, the Bonferroni-significant associations between statins and glycans were replicated in the previously excluded group of MZ discordant twins using the same model. If the regression coefficients were the same direction in both analyses, the results were combined using inverse-variance fixed effect meta-analysis.
For the JUPITER study the differences were calculated between glycan values after and before the randomized allocation of placebo or rosuvastatin. Differences between the placebo and rosuvastatin groups were tested using the Mann Whitney U test.
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Results
Association of statins with IgG glycome in the TwinsUK cohort
IgG glycome composition and information about the use of statins was available for 2247 individuals from the TwinsUK cohort. The demographic characteristics of the study population are summarized in Table 1 . Released and 2-AB labeled IgG glycans were analyzed by HILIC-UPLC. Chromatograms obtained for
IgG glycans were separated in 24 glycan peaks, which correspond to different glycan structures (GP1-24, Figure 1 ). In addition to 24 directly measured glycan traits, 53 derived traits were calculated as described previously [7] (Supplementary Table 1 ).
These derived traits represent common biologically meaningful features (fucosylation, bisection, agalactosylation, monogalactosylation, digalactosylation, sialylation, etc.) shared among several measured glycans. analyses, we combined the results using inverse-variance fixed effect meta-analysis. Table 2 presents the list of glycans significantly associated with statins use in the discovery cohort, the validation results in the MZ discordant cohort and the metaanalysis results. The use of statins was associated with a small increase in GP6 and GP6 n , which contain core-fucosylated biantennary glycan structure with bisecting Nacetylglucosamine (FA2B), together with biantennary monogalactosylated glycan structure (A2G1) in a much smaller amount, and a small decrease in GP18, which contains core-fucosylated biantennary digalactosylated monosialylated glycan structure (FA2G2S1), together with biantennary digalactosylated monosialylated glycan structure with bisecting N-acetylglucosamine (A2BG2S1) in a much smaller amount [7] . Table 2 ). For atorvastatin no associations were found (Supplementary Table 2 ).
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Replication in the KORA cohort
We aimed to replicate the associations found in the TwinsUK population in 1665 individuals from KORA cohort (257 cases and 1408 controls, Table 1 ). IgG Fc tryptic N-glycopeptides were measured by LC-ESI-MS, which enables glycosylation measurement of IgG Fc region at subclass-specific level. Linear regressions were applied to study the previously found significant associations between the use of statins and the glycan traits. Nominally statistically significant associations have been confirmed for two of three glycan traits (confirmed for FA2B in total and neutral IgG glycans, not confirmed for FA2G2S1) for each IgG subclass (IgG1, IgG2/3, IgG4) (Table
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2). The regression coefficients were in the same direction, and of similar magnitude as found in the TwinsUK population.
Association of rosuvastatin with IgG Fc N-glycopeptides and total plasma proteins Nglycome in the JUPITER study
JUPITER is a randomized double-blind placebo-controlled study investigating the use of rosuvastatin versus placebo in the primary prevention of cardiovascular disease [19] . In a subset of JUPITER, we examined the effect of one year of rosuvastatin 20mg/day on the glycosylation of IgG Fc region at subclass-specific level (analysis of IgG tryptic glycopeptides by LC-ESI-MS). The analysis was performed on 97 individuals -47 on placebo and 50 on rosuvastatin (three individuals in the placebo group were excluded from the analysis because of low signal intensity) (Table 1) . Derived traits that represent common biologically meaningful features (fucosylation, bisection, agalactosylation, monogalactosylation, digalactosylation and sialylation) shared among several measured glycans were calculated for each subclass group as described previously [29] (Supplementary Table 1) .
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We investigated the differences between the placebo and the rosuvastatin group (Supplementary Figure 1) . For each derived trait of each IgG subclass (IgG1, IgG2/3, IgG4), differences were calculated between glycan values after and before the placebo/rosuvastatin treatment. We found no statistically significant differences between the two groups (Supplementary Table 3 ). We also tried to replicate the associations found in the TwinsUK population (for glycan traits corresponding to FA2B and FA2G2S1). However, treatment with rosuvastatin had no effect on these glycan traits in any of the IgG subclasses.
To determine whether rosuvastatin induces a more general change in glycosylation of multiple proteins, we searched for associations between N-glycome of total plasma proteins (46 glycan peaks of enzymatically released, 2-AB labeled Nglycans obtained by HILIC-UPLC, Supplementary Figure 2 ) and the use of rosuvastatin in the same individuals from the JUPITER study (Supplementary Figure 3) . We found no significant difference in N-glycosylation of plasma proteins between the studied groups (Supplementary Table 4) .
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Discussion
The aim of this study was to investigate the possible association of statin use with N-glycosylation of IgG in the TwinsUK and KORA populations. Afterwards we investigated the same association for only one statin (rosuvastatin) in a subset of participants from the randomized double-blind placebo-controlled JUPITER study.
In the TwinsUK population, three glycan traits (GP6, GP6 n and GP18) were found to be significantly associated with statin use in the discovery cohort, and they remained significant after the meta-analysis of the results from the discovery cohort and the validation results from the MZ discordant cohort. The use of statins was associated with higher levels of GP6 and GP6 n (which mostly contain core- glycopeptides did not reach statistical significance.
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
25
FA2B is one of the IgG's agalactosylated glycans. Glycans that lack terminal galactose activate complement and make IgG pro-inflammatory [30] [31] [32] . Also, FA2B
is one of three glycans that change considerably with age (along with FA2G2 and FA2BG2) and the combination of these three glycans can explain up to 58% of variance in chronological age [33] . FA2B is increasing with age, and it is also increasing in many different pathological conditions (e.g. autoimmune diseases [34, 35] , kidney disease [14] and cancer [36] ). In contrast, FA2G2S1, the major sialylated glycan in IgG glycome, is decreasing with age [33] , and it was also reported to be decreased in patients with systemic lupus erythematosus [34] and kidney disease [14] . Terminal α2,6-sialylation of IgG glycans decreases the ability of IgG to bind Fcγ receptors (FcγRs), which increases expression of inhibitory FcγRIIB and is anti-inflammatory [21, 37] . However, these findings have not been confirmed in all studies [22, 38, 39] . Taken together, these suggest that a pro-inflammatory pattern of
IgG glycan was found in association with statins in both the TwinUK and KORA studies.
Glycosylation is known to be affected by factors such as: expression levels, localization and substrate affinities and specificities of the glyco-enzymes, as well as abundance and trafficking of glycoprotein substrates and activated sugar donors concentrations [40] [41] [42] [43] . Therefore, the observed changes in N-glycan profiles may be 26 the result of slight alterations in the levels of glycosyltransferases and glycosidases, caused by statin use or some other underlying factor.
Patients who take statins usually have dyslipidemia and other CVD risk factors. Hence, there is a possibility that the associations that we found could be due to the connection between the IgG glycans and the lipid profile or other potential confounders, which was previously reported in some studies [33, 44] . Therefore, to test whether the associations found between statin use and IgG glycosylation are the consequence of the direct influence of statin therapy, we investigated this association for randomly allocated rosuvastatin therapy versus placebo in the JUPITER trial. We found no statistically significant differences between the placebo and rosuvastatin groups after one year on study treatment. We also analyzed association between total plasma proteins N-glycome and rosuvastatin in the same individuals from the JUPITER study to determine whether rosuvastatin induces a more general change in glycosylation of multiple proteins. We found no difference in plasma glycosylation.
When we explored the association between individual statin use and IgG glycan traits in the TwinsUK cohort for simvastatin and atorvastatin, we found 31 nominally significantly associated glycan traits with simvastatin use and no glycan traits associated with atorvastatin use (Supplementary Table 2 ). Although none of
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27 them remained significant after correction for multiple testing, the number of cases was too small (≈100) to detect a small effect size. Therefore, there is an indication that different statins may differently influence IgG N-gycome and that could be the reason we did not find any associations between rosuvastatin and IgG glycan traits.
Another explanation might be that the association between statin use and IgG glycans we found in the TwinsUK and KORA cohorts was confounded by the lipid profile or other CVD risk factors, which drove the pro-inflammatory changes that we saw, and that those effects were eliminated in the randomized double-blind placebo-controlled JUPITER study.
Conclusion
In the TwinsUK and KORA cohorts, statin use was associated with a small increase of pro-inflammatory IgG glycan, although this finding was not confirmed in a subset of participants from the JUPITER trial. There are several possible collected trial data and monitored sites but had no role in the design or conduct of the current study, including data analysis or interpretation, drafting or editing this report, or in preparation, review or the decision to submit the manuscript for publication.
